Tango Therapeutics (TNGX) Revenue (2020 - 2025)

Tango Therapeutics' Revenue history runs 6 years deep, the most recent figure standing at $53.8 million for Q3 2025.

• On a quarterly basis, Revenue rose 363.61% year-over-year to $53.8 million in Q3 2025; TTM through Mar 2026 was $57.0 million, a 39.04% increase from a year earlier, with the FY2025 full-year figure at $62.4 million, up 48.29% from the prior year.
• Revenue rose to $53.8 million in Q3 2025 per TNGX's latest filing, from $3.2 million in the prior quarter.
• Across five years, Revenue topped out at $53.8 million in Q3 2025 and bottomed at $3.2 million in Q2 2025.
• The 5-year median for Revenue is $6.4 million (2022), against an average of $10.7 million.
• Biggest YoY gain for Revenue was 363.61% in 2025; the steepest drop was 83.99% in 2025.
• Year by year, Revenue stood at $5.7 million in 2021, then rose by 12.16% to $6.4 million in 2022, then declined by 15.29% to $5.4 million in 2023, then decreased by 24.19% to $4.1 million in 2024, then soared by 1207.04% to $53.8 million in 2025.
• Per Business Quant, the three latest TNGX Revenue figures stand at $53.8 million (Q3 2025), $3.2 million (Q2 2025), and $5.4 million (Q1 2025).